The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability A Scalfari, A Neuhaus, A Degenhardt, GP Rice, PA Muraro, M Daumer, ... Brain 133 (7), 1914-1929, 2010 | 862 | 2010 |
Abnormal associative plasticity of the human motor cortex in writer’s cramp A Quartarone, S Bagnato, V Rizzo, HR Siebner, V Dattola, A Scalfari, ... Brain 126 (12), 2586-2596, 2003 | 490 | 2003 |
Onset of secondary progressive phase and long-term evolution of multiple sclerosis A Scalfari, A Neuhaus, M Daumer, PA Muraro, GC Ebers Journal of Neurology, Neurosurgery & Psychiatry 85 (1), 67-75, 2014 | 383 | 2014 |
Mortality in patients with multiple sclerosis A Scalfari, V Knappertz, G Cutter, DS Goodin, R Ashton, GC Ebers Neurology 81 (2), 184-192, 2013 | 370 | 2013 |
Age and disability accumulation in multiple sclerosis A Scalfari, A Neuhaus, M Daumer, GC Ebers, PA Muraro Neurology 77 (13), 1246-1252, 2011 | 304 | 2011 |
Clinical prognostic factors in multiple sclerosis: a natural history review A Degenhardt, SV Ramagopalan, A Scalfari, GC Ebers Nature Reviews Neurology 5 (12), 672-682, 2009 | 220 | 2009 |
Smouldering multiple sclerosis: the ‘real MS’ G Giovannoni, V Popescu, J Wuerfel, K Hellwig, E Iacobaeus, MB Jensen, ... Therapeutic advances in neurological disorders 15, 17562864211066751, 2022 | 181 | 2022 |
Early relapses, onset of progression, and late outcome in multiple sclerosis A Scalfari, A Neuhaus, M Daumer, GC DeLuca, PA Muraro, GC Ebers JAMA neurology 70 (2), 214-222, 2013 | 138 | 2013 |
The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis A Scalfari, C Romualdi, RS Nicholas, M Mattoscio, R Magliozzi, A Morra, ... Neurology 90 (24), e2107-e2118, 2018 | 129 | 2018 |
The relationship of age with the clinical phenotype in multiple sclerosis A Scalfari, C Lederer, M Daumer, R Nicholas, GC Ebers, PA Muraro Multiple Sclerosis Journal 22 (13), 1750-1758, 2016 | 86 | 2016 |
Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis G Filippini, C Del Giovane, M Clerico, O Beiki, M Mattoscio, F Piazza, ... Cochrane database of systematic reviews, 2017 | 75 | 2017 |
Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients M Calabrese, R Reynolds, R Magliozzi, M Castellaro, A Morra, A Scalfari, ... PloS one 10 (8), e0135428, 2015 | 70 | 2015 |
The CSF profile linked to cortical damage predicts multiple sclerosis activity R Magliozzi, A Scalfari, AI Pisani, S Ziccardi, D Marastoni, FB Pizzini, ... Annals of neurology 88 (3), 562-573, 2020 | 64 | 2020 |
Autologous hematopoietic stem cell transplantation in active multiple sclerosis: a real-world case series RS Nicholas, EE Rhone, A Mariottini, E Silber, O Malik, V Singh-Curry, ... Neurology 97 (9), e890-e901, 2021 | 36 | 2021 |
AW eb‐based tool for personalized prediction of long‐term disease course in patients with multiple sclerosis I Galea, C Lederer, A Neuhaus, PA Muraro, A Scalfari, N Koch‐Henriksen, ... European journal of neurology 20 (7), 1107-1109, 2013 | 33 | 2013 |
Acute inflammatory diseases of the central nervous system after SARS-CoV-2 vaccination AG Francis, K Elhadd, V Camera, M Ferreira dos Santos, C Rocchi, ... Neurology: Neuroimmunology & Neuroinflammation 10 (1), e200063, 2022 | 32 | 2022 |
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab S Pfeuffer, T Ruck, R Pul, L Rolfes, C Korsukewitz, M Pawlitzki, ... Journal of Neurology, Neurosurgery & Psychiatry 92 (9), 1007-1013, 2021 | 30 | 2021 |
Pharmacological approaches to the management of secondary progressive multiple sclerosis A Nandoskar, J Raffel, AS Scalfari, T Friede, RS Nicholas Drugs 77, 885-910, 2017 | 26 | 2017 |
A novel prognostic score to assess the risk of progression in relapsing− remitting multiple sclerosis patients AI Pisani, A Scalfari, F Crescenzo, C Romualdi, M Calabrese European journal of neurology 28 (8), 2503-2512, 2021 | 25 | 2021 |
MS progression is predominantly driven by age-related mechanisms–YES A Scalfari Multiple Sclerosis Journal 25 (7), 902-904, 2019 | 21 | 2019 |